These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38602320)

  • 1. The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
    Ding XH; Xiao Y; Chen F; Liu CL; Fu T; Shao ZM; Jiang YZ
    Brief Bioinform; 2024 Mar; 25(3):. PubMed ID: 38602320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer.
    Zhou YF; Xiao Y; Jin X; Di GH; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer.
    Karn T; Jiang T; Hatzis C; Sänger N; El-Balat A; Rody A; Holtrich U; Becker S; Bianchini G; Pusztai L
    JAMA Oncol; 2017 Dec; 3(12):1707-1711. PubMed ID: 28750120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer.
    Lu Z; Chen H; Jiao X; Wang Y; Wu L; Sun H; Li S; Gong J; Li J; Zou J; Yang K; Hu Y; Mao B; Zhang L; Zhang X; Peng Z; Lu M; Wang Z; Zhang H; Shen L
    Genome Med; 2021 Nov; 13(1):175. PubMed ID: 34732240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common
    Lim WC; Marques Da Costa ME; Godefroy K; Jacquet E; Gragert L; Rondof W; Marchais A; Nhiri N; Dalfovo D; Viard M; Labaied N; Khan AM; Dessen P; Romanel A; Pasqualini C; Schleiermacher G; Carrington M; Zitvogel L; Scoazec JY; Geoerger B; Salmon J
    Front Immunol; 2023; 14():1265469. PubMed ID: 38318504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
    Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
    Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
    Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
    Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
    Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
    Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.
    Garrido MA; Rodriguez T; Zinchenko S; Maleno I; Ruiz-Cabello F; Concha Á; Olea N; Garrido F; Aptsiauri N
    Immunogenetics; 2018 Nov; 70(10):647-659. PubMed ID: 30145665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Less correlation between mismatch repair proteins deficiency and decreased expression of HLA class I molecules in endometrial carcinoma: a different propensity from colorectal cancer.
    Mariya T; Kubo T; Hirohashi Y; Yanagawa J; Tabuchi Y; Matsuo K; Furumura K; Morita R; Nakatsugawa M; Kanaseki T; Tsukahara T; Hasegawa T; Saito T; Torigoe T
    Med Mol Morphol; 2021 Mar; 54(1):14-22. PubMed ID: 32410009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D; Jia H; Zhang Z; Li S
    Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer.
    Han SH; Kim M; Chung YR; Woo JW; Choi HY; Park SY
    Sci Rep; 2022 Nov; 12(1):20367. PubMed ID: 36437379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
    Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
    Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.
    Qiao W; Jia Z; Guo W; Liu Q; Guo X; Deng M
    Mol Diagn Ther; 2023 Sep; 27(5):573-582. PubMed ID: 37464212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.
    Yam C; Mani SA; Moulder SL
    Oncologist; 2017 Sep; 22(9):1086-1093. PubMed ID: 28559413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic regulation of invasion by STAT3 in triple negative breast cancer.
    McDaniel JM; Varley KE; Gertz J; Savic DS; Roberts BS; Bailey SK; Shevde LA; Ramaker RC; Lasseigne BN; Kirby MK; Newberry KM; Partridge EC; Jones AL; Boone B; Levy SE; Oliver PG; Sexton KC; Grizzle WE; Forero A; Buchsbaum DJ; Cooper SJ; Myers RM
    Oncotarget; 2017 Jan; 8(5):8226-8238. PubMed ID: 28030809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
    Sasaki R; Horimoto Y; Yanai Y; Kurisaki-Arakawa A; Arakawa A; Nakai K; Saito M; Saito T
    Anticancer Res; 2021 Apr; 41(4):2133-2140. PubMed ID: 33813424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.